Related Experiment Video
Updated: Jun 12, 2025
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022
Simon John Christoph Soerensen1,2, Shufeng Li3,4, Marvin E Langston5
1Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. simonjcs@stanford.edu.
Background:
Clinical guidelines favor MRI before prostate biopsy due to proven benefits. However, adoption patterns across the US are unclear.
Methods:
This study used the Merative™ Marketscan® Commercial & Medicare Databases to analyze 872,829 prostate biopsies in 726,663 men from 2007-2022. Pre-biopsy pelvic MRI within 90 days was the primary outcome. Descriptive statistics and generalized estimating equations assessed changes over time, urban-rural differences, and state-level variation.
Results:
Pre-biopsy MRI utilization increased significantly from 0.5% in 2007 to 35.5% in 2022, with faster adoption in urban areas (36.1% in 2022) versus rural areas (28.3% in 2022). Geographic disparities were notable, with higher utilization in California, New York, and Minnesota, and lower rates in the Southeast and Mountain West.
Conclusions:
The study reveals a paradigm shift in prostate cancer diagnostics towards MRI-guided approaches, influenced by evolving guidelines and clinical evidence. Disparities in access, particularly in rural areas and specific regions, highlight the need for targeted interventions to ensure equitable access to advanced diagnostic techniques.
Insights
Pre-biopsy MRI use for prostate cancer diagnosis has surged nationwide, yet significant disparities persist between urban and rural areas. Targeted interventions are needed to ensure equitable access to advanced imaging techniques.
Area of Science:
- Urology
- Radiology
- Health Services Research
Background:
- Clinical guidelines recommend magnetic resonance imaging (MRI) before prostate biopsy due to established benefits.
- Understanding the real-world adoption of pre-biopsy MRI across the United States is crucial.
Purpose of the Study:
- To analyze national trends in pre-biopsy pelvic MRI utilization for prostate cancer diagnostics.
- To identify disparities in MRI adoption based on geographic location (urban vs. rural) and state.
Main Methods:
- Analysis of 872,829 prostate biopsies in 726,663 men from 2007-2022 using the Merative™ Marketscan® databases.
- Primary outcome: pre-biopsy pelvic MRI within 90 days of biopsy.
- Statistical methods included descriptive statistics and generalized estimating equations to assess temporal, urban-rural, and state-level variations.
Main Results:
- Pre-biopsy MRI utilization dramatically increased from 0.5% in 2007 to 35.5% in 2022.
- Adoption was faster in urban areas (36.1% in 2022) compared to rural areas (28.3% in 2022).
- Significant geographic disparities observed, with higher utilization in states like California, New York, and Minnesota, and lower rates in the Southeast and Mountain West.
Conclusions:
- A significant shift towards MRI-guided approaches in prostate cancer diagnostics is evident, driven by updated guidelines and evidence.
- Disparities in access to pre-biopsy MRI, especially in rural regions and specific geographic areas, necessitate targeted interventions.
- Ensuring equitable access to advanced diagnostic techniques like MRI is essential for all patients.
More Related Videos
06:08A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
05:49Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
